AI assistant
Evotec SE — Regulatory Filings 2012
Oct 8, 2012
151_rns_2012-10-08_d905e794-1534-4118-9978-31f37220ed49.html
Regulatory Filings
Open in viewerOpens in your device viewer
News Details
Corporate | 8 October 2012 07:26
Evotec receives Milestone in Drug Discovery Collaboration
Evotec AG / Key word(s): Alliance
08.10.2012 / 07:26
Hamburg, Germany - 08 October 2012: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX) today announced that it has received a pre-clinical milestone
from its Drug Discovery Collaboration with Novartis. No financial details
were given.
Dr Mario Polywka, Chief Operating Officer of Evotec, said: 'We are pleased
to have received a milestone from the collaboration with Novartis that
started in 2008. This is further recognition of our track record in
advancing compounds towards the clinic with our collaborators.'
About the Novartis Collaboration
Under the terms of the agreement, Evotec is responsible for progressing the
program up to pre-clinical development and Novartis will then have the
responsibility for all clinical development activities, manufacture and
commercialization of the compounds. In return for Evotec's contributions to
the research program, Evotec received an upfront payment and research
funding and is eligible for pre-clinical and clinical milestone payments
that could exceed $ 28 million. In addition, Novartis will pay royalties on
sales of any marketed products resulting from the collaboration.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Dr Mario Polywka, Chief Operating Officer, Phone: +44.(0)1235.441676,
[email protected]
End of Corporate News
08.10.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
187873 08.10.2012